Truist lowered the firm’s price target on OrthoPediatrics (KIDS) to $22 from $26 and keeps a Hold rating on the shares after its Q2 results. The firm continues to like the momentum drivers and ramping profit story for this uniquely positioned asset, but it will take more steady/larger magnitude of beats/raises to support multiple expansion, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KIDS:
- OrthoPediatrics price target lowered to $39 from $40 at BTIG
- OrthoPediatrics Corp. Achieves Record Revenue Milestone
- OrthoPediatrics Highlights Strategic Focus in Presentations
- OrthoPediatrics reports Q2 EPS (11c), consensus (28c)
- OrthoPediatrics raises FY25 revenue view to $237M-$242M from $236M-$242M